What Is ARA-290?
What is ARA-290 (cibinetide)? Erythropoietin-derived research peptide overview.
ARA-290 is a specialized synthetic peptide derived from the structure of erythropoietin (EPO), specifically engineered to target the innate repair receptor (IRR) to mitigate tissue damage and inflammation. Researchers exploring what is ARA-290 often focus on its potential to offer cytoprotective benefits without the erythropoietic side effects typically associated with full-length EPO. By selectively activating pathways involved in cellular protection and repair, this compound has become a primary subject in studies involving neuropathic pain and chronic inflammatory conditions.
The Molecular Origins of ARA-290
To understand what is ARA-290, one must first look at its precursor, the glycoprotein erythropoietin. While EPO is primarily known for its role in red blood cell production (hematopoiesis) via the homodimeric EPO receptor, it was discovered that EPO also possesses substantial tissue-protective properties. These protective actions are mediated through a different receptor configuration known as the Innate Repair Receptor (IRR).
ARA-290, also referred to as Cibinetide, is an 11-amino acid peptide that mimics the three-dimensional structure of the B-helix of the EPO molecule. Unlike full EPO, ARA-290 does not bind to the homodimeric EPO receptor. Consequently, it does not stimulate erythropoiesis, avoiding the risks of increased blood viscosity or thrombosis in research models. Instead, it binds with high affinity to the IRR (a heteromer of the EPO receptor and the CD131 common beta subunit), which is typically expressed only during periods of cellular stress, injury, or inflammation.
Mechanism of Action: The Innate Repair Receptor (IRR)
The primary mechanism of ARA-290 involves the specific activation of the IRR, which triggers a cascade of intracellular signaling pathways designed to stabilize cellular environments. Upon binding, ARA-290 initiates anti-inflammatory and anti-apoptotic signals.
- Inhibition of Pro-inflammatory Cytokines: Research indicates that ARA-290 suppresses the production of TNF-alpha, IL-6, and other inflammatory mediators that exacerbate tissue damage.
- Activation of Jak2/STAT5 Pathways: This pathway helps in maintaining mitochondrial membrane potential and preventing the activation of caspases, which are responsible for programmed cell death.
- Neuroprotection: By targeting the IRR expressed on peripheral nerves, the peptide may prevent the retraction of small nerve fibers, a hallmark of small fiber neuropathy (SFN).
This focused action makes it a distinct research tool compared to general regenerative peptides like BPC-157, which operates through broader angiogenic and growth factor modulation.
Research Findings in Neuropathic Pain
A significant portion of clinical and laboratory research regarding ARA-290 has focused on small fiber neuropathy, particularly in the context of sarcoidosis and diabetes. Small nerve fibers are responsible for transmitting pain and temperature sensations; when damaged, they cause debilitating chronic pain and autonomic dysfunction.
In various phase II studies, ARA-290 has demonstrated the ability to increase corneal nerve fiber density (a standard proxy for systemic nerve fiber density) and significantly reduce pain scores in subjects with sarcoidosis-associated SFN. Unlike traditional analgesics that merely mask pain signals, the data suggests that ARA-290 may address the underlying pathology by promoting the survival and regeneration of damaged nerve fibers.
Furthermore, animal studies involving Type 2 diabetes models have shown that ARA-290 can improve glucose metabolism and reduce the inflammatory markers associated with diabetic retinopathy. This suggests that the peptide’s utility extends beyond nerve protection into broader metabolic and vascular protection.
ARA-290 in Wound Healing and Tissue Repair
Beyond its neurological applications, ARA-290 is frequently studied for its role in accelerated tissue repair. Because the IRR is expressed in various tissues following trauma, the peptide has been applied to research involving myocardial infarction, renal ischemia, and cutaneous wounds.
In models of chronic non-healing wounds, ARA-290 has been shown to improve the quality of the extracellular matrix and enhance the recruitment of progenitor cells to the site of injury. While TB-500 is often the focus of research regarding actin-mediated cell migration, ARA-290 offers a complementary approach by reducing the localized "cytokine storm" that often halts the transition from the inflammatory phase to the proliferative phase of healing.
Comparison to Related Research Compounds
In the landscape of recovery research, ARA-290 occupies a unique niche. While growth hormone secretagogues like CJC-1295 or HGH focus on systemic anabolic signaling and insulin-like growth factor-1 (IGF-1) elevation, ARA-290 is purely cytoprotective and anti-inflammatory.
It is often contrasted with: * [BPC-157](/research/hubs/bpc-157): Focuses on gastrointestinal and musculoskeletal repair via nitric oxide pathways. * [SS-31](/research/hubs/ss-31): A mitochondria-targeted peptide that, like ARA-290, addresses oxidative stress but does so by stabilizing cardiolipin rather than receptor-mediated signaling. * Glutathione: A master antioxidant used in research to reduce oxidative stress, whereas ARA-290 actively triggers a biological repair program via the IRR.
Handling, Reconstitution, and Laboratory Protocols
ARA-290 is typically supplied as a lyophilized (freeze-dried) powder to ensure molecular stability. Because it is a peptide, it is highly sensitive to temperature and physical agitation.
* Reconstitution: Laboratory protocols generally utilize Bacteriostatic Water or sterile saline. The peptide should be reconstituted by allowing the diluent to trickle down the side of the vial to avoid shearing the delicate molecular chains. * Storage: In its lyophilized state, ARA-290 is stable at room temperature for short periods but should be stored at -20°C for long-term preservation. Once reconstituted, it must be refrigerated at 2-8°C and used within a specific timeframe (usually 14–28 days) to maintain potency. * Concentration: Research dosages fluctuate significantly based on the model (e.g., murine vs. porcine models), typically ranging from 1 mg/kg to 30 mg/kg in specialized animal studies.
Limitations and Future Outlook
Despite the promising data in neuropathic pain and inflammatory modulation, ARA-290 research faces several challenges. The peptide has a relatively short half-life in circulation, necessitating frequent administration in laboratory settings to maintain stable plasma levels.
Additionally, while the lack of erythropoietic activity is a benefit for safety, it also means the peptide does not assist in oxygen transport, a common misconception among those familiar with its parent molecule, EPO. Current research is expanding into the realms of autoimmune diseases, such as systemic lupus erythematosus (SLE) and rheumatoid arthritis, where the IRR may play a role in preventing end-organ damage from chronic inflammation.
Frequently Asked Questions
Q: Does ARA-290 increase red blood cell count? No. ARA-290 is specifically designed to bypass the homodimeric EPO receptor responsible for erythropoiesis. It only binds to the Innate Repair Receptor (IRR), meaning it does not stimulate the production of red blood cells or increase hematocrit levels.
Q: How does ARA-290 differ from standard EPO? Erythropoietin (EPO) is a large protein that stimulates both red blood cell production and tissue repair. ARA-290 is a short 11-amino acid peptide fragment that provides the tissue-protective benefits of EPO without causing the hematological changes associated with the full-length hormone.
Q: In what research models is ARA-290 most commonly used? ARA-290 is primarily utilized in models of neuropathic pain, small fiber neuropathy, sarcoidosis, type 2 diabetes, and various ischemia-reperfusion injury models. It is also being investigated for its potential to reduce inflammation in pancreatic islet transplantation.
Q: What is the stability of ARA-290 after reconstitution? Once reconstituted in a sterile buffer or bacteriostatic water, ARA-290 is susceptible to degradation. Researchers typically store the liquid solution at 2-8°C and aim to complete the study sequence within 30 days to ensure the peptide's structural integrity and binding affinity remain optimal.
Research Use Only. This content is intended for laboratory and research purposes only. Not for human consumption, diagnosis, or treatment.
Related Research Articles
TB-500 Expanded Research Guide 2026
TB-500's G-actin sequestration mechanism is deceptively simple — by binding monomeric actin and redirecting the cell's cytoskeletal dynamics, it promotes cell migration in ways that have proven relevant across tissue repair, cardiac, and neurological research contexts far beyond its original wound healing focus.
GHK-Cu vs BPC-157 Research Comparison 2026
GHK-Cu and BPC-157 are frequently compared because both appear in recovery and skin research — but their mechanisms are so distinct that they address different biological questions entirely, which is why both appear together in the KLOW Blend rather than being treated as alternatives.
KPV Complete Research Guide 2026
KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone, studied for targeted NF-κB pathway inhibition — a highly specific anti-inflammatory mechanism that distinguishes it from the broader tissue repair effects of BPC-157 and TB-500.
ARA-290 Complete Research Guide 2026
ARA-290 is an 11-amino-acid peptide derived from erythropoietin's three-dimensional structure, designed to activate the innate repair receptor rather than the erythropoietin receptor — separating the tissue-protective and neuroprotective EPO effects from its red blood cell-stimulating activity.
GHK-Cu Complete Research Guide 2026
GHK-Cu (copper peptide) is one of the most mechanistically distinct compounds in the research catalog — its activity is inseparable from the copper coordination chemistry that gives it both its research properties and its unusual stability profile compared to standard amino acid peptides.
BPC-157 vs TB-500 — Which Recovery Peptide to Research in
Researchers comparing BPC-157 and TB-500 often frame it as a choice between two compounds. The more accurate framing is a choice between two mechanisms — and once you understand what each one actually does, the research case for studying both together becomes obvious.
Neutral, moderated research discussion. Laboratory use only.
More compound guides, hubs, and educational research materials.